Table 2.
Selected preclinical or clinical trials of therapeutic vaccines against chronic non-communicable diseases
| Therapeutic vaccines for cancers | |||||
|---|---|---|---|---|---|
| Vaccine type | Vaccine Formulation | Combination agents | Condition | Identifier/ reference | Phase/status |
| Personalized peptide vaccine | NeoVax (neoantigen + Poly-ICLC) | Ipilimumab | Kidney Cancer | NCT02950766 | Phase I Recruiting |
| NEO-PV-01 (neoantigen) + Poly-ICLC | Nivolumab | Melanoma, lung, or bladder cancer | NCT02897765 | Phase Ib Completed | |
| GRT-C903 (shared neoantigen prime)/GRT-R904(shared neoantigen boost) | Nivolumab/ipilimumab | NSCLC, colorectal cancer, pancreatic cancer, shared neoantigen-positive solid tumors | NCT03953235 | Phase I/II Recruiting | |
| GRT-C901(patient-specific neoantigen prime)/GRT-R902(patient-specific neoantigen boost) | Nivolumab/ ipilimumab | NSCLC, colorectal cancer, gastroesophageal, adenocarcinoma, urothelial carcinoma, | NCT03639714 | Phase I/II Active, not recruiting | |
| Multiple candidate tumor-derived neoantigens | Pembrolizumab | Advanced Cancer | NCT03568058 | Phase Ib Active, not recruiting | |
| GEN-009 (neoantigen) + Poly-ICLC | Nivolumab/ Pembrolizumab | Cutaneous melanoma,NSCLC, SCC ofhead and neck, urothelial carcinoma, RCC | NCT03633110 | Phase I/IIa Completed | |
| PGV001 (patient specific long peptides+ helper peptides) + Poly-ICLC | Atezolizumab | Urothelial/bladder cancer | NCT03359239 | Phase I Completed | |
| NeoVax(peptides) plus Montanide | Nivolumab/Ipilimumab | Melanoma | NCT03929029 | Phase Ib Recruiting | |
| personalized peptide | Pembrolizumab +imiquimod | Pancreatic and colorectal cancer (advanced) | NCT02600949 | Phase I Recruiting | |
| PGV001(patient specific long peptides+ helper peptides) + Poly-ICLC | Lenalidomide | Solid Tumors | NCT02721043 | Phase I Completed | |
| CDX-1401(DEC-205/NY-ESO-1 Fusion Protein) + Poly-ICLC | Recombinant Flt3 Ligand | Stage IIB-IV melanoma | NCT02129075 | Phase II Completed | |
| mRNA-based neoantigen vaccine | RO7198457(mRNA-based) | Atezolizumab | Locally advanced or metastatic tumor | NCT03289962 | Phase Ia/Ib Active, not recruiting |
| mRNA-4157(lipid encapsulated RNA) | Pembrolizumab | Solid Tumors | NCT03313778 | Phase I Recruiting | |
| mRNA-4157(lipid encapsulated RNA) | Pembrolizumab | Melanoma | NCT03897881 | Phase II Active, not recruiting | |
| RO7198457(mRNA-based) | Atezolizumab+ mFOLFIRINOX | Pancreatic Cancer | NCT04161755 | Phase I Active, not recruiting | |
| DNA-based neoantigen vaccine | Neoantigen DNA (TDS-IM system) | Durvalumab | TNBC | NCT03199040 | Phase I Active, not recruiting |
| GNOS PV02 (Personalized Neoantigen DNA Vaccine) | Pembrolizumab+INO9012(plasmid encoded IL-12) | HCC | NCT04251117 |
Phase I/IIa Recruiting |
|
| Therapeutic vaccines for hypertension | |||||
| Protein vaccine | PMD3117(Ang I analog with keyhole limpet haemocyanin(KLH)) | aluminum hydroxide | [152] | Phase II Completed | |
| Peptide vaccine | CYT006-AngQb (angiotensin II- conjugated to the VLP Qβ) | – | hypertension | [153] | Phase I Completed |
| – | Essential Hypertension | NCT00500786 | Phase I/II Completed | ||
| ATR12181 (peptide from rat AT1a receptor) | Complete Freund’s adjuvant | Spontaneously hypertension (in rat) | [154] | Preclinic trail | |
| ATRQβ-001(a peptide derived from human Ang II receptor type 1 conjugated with VLP Qβ) | Aluminum hydroxide | Hypertensive Animals | [155] | Preclinic trail | |
| DNA Vaccine | AGMG0201 (expressing angiotensin II) | – | Mild to moderate essential hypertension | ACTRN12617001192370 [156] | Phase I/IIa Completed |
| Therapeutic vaccines for Alzheimer’s disease | |||||
| Peptide vaccine | ABvac40(a conjugate of Aβx-40 with KLH) | Aluminum hydroxide | Mild to moderate Alzheimer’s disease | NCT03113812 | Phase I Completed |
| Aluminum hydroxide | Mild cognitive impairment Alzheimer Disease | NCT03461276 |
Phase II Active, not recruiting |
||
| AADvac1 (a synthetic peptide from a tau protein sequence coupled to KLH) | Aluminum hydroxide | Alzheimer’s Disease | NCT02031198 | Phase I Completed | |
| Aluminum hydroxide | Alzheimer’s Disease | NCT02579252 | Phase II Completed | ||
| UB311 | CpG ODN and alum | Alzheimer’s Disease | NCT00965588 | Phase I Completed | |
| CpG ODN and alum | Mild Alzheimer’s Disease | NCT02551809 | Phase II Completed | ||
| Therapeutic vaccines for other diseases | |||||
| Peptide vaccines | tgG-DSE2lim and tgG-DSE5b | Emulsigen-D | Amyotrophic lateral sclerosis (ALS) in mice | [157] | Preclinical trial |
| T-cell epitopes within DPP4 conjugated to KLH | Complete/incomplete Freund’s adjuvant | Type 2 diabetes mellitus in mice | [158] | Preclinical trial | |
| PCSK9Qβ-003(PCSK9 peptide conjugated with VLP Qβ) | Aluminum hydroxide | Dyslipidemia in mice | [159] | Preclinical trial | |
Source: The clinical trials were from ClinicalTrials.gov or Australian New Zealand Clinical Trials Registry (ANZCTR)